194 related articles for article (PubMed ID: 12180495)
1. MK-383 (tirofiban) induces a GPIIb/IIIa receptor conformation which differs from the resting and activated receptor.
Barlage S; Wimmer A; Pfeiffer A; Rothe G; Schmitz G
Platelets; 2002 May; 13(3):133-40. PubMed ID: 12180495
[TBL] [Abstract][Full Text] [Related]
2. Tirofiban blocks platelet adhesion to fibrin with minimal perturbation of GpIIb/IIIa structure.
Hantgan RR; Stahle MC; Jerome WG; Nagaswami C; Weisel JW
Thromb Haemost; 2002 May; 87(5):910-7. PubMed ID: 12038797
[TBL] [Abstract][Full Text] [Related]
3. [Conformational changes of the platelet membrane glycoprotein IIb-IIIa complex stimulated by a monoclonal antibody to the N-terminal segment of glycoprotein IIIa].
Khaspekova SG; Vyzova TV; Lukin VV; Tikhomirov OIu; Berndt M; Kouns W; Mazurov AV
Biokhimiia; 1996 Mar; 61(3):412-28. PubMed ID: 8724599
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of fibrinogen binding and surface recruitment of GpIIb/IIIa as dose-dependent effects of the RGD-mimetic MK-852.
Wittig K; Rothe G; Schmitz G
Thromb Haemost; 1998 Mar; 79(3):625-30. PubMed ID: 9531053
[TBL] [Abstract][Full Text] [Related]
5. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists.
Bassler N; Loeffler C; Mangin P; Yuan Y; Schwarz M; Hagemeyer CE; Eisenhardt SU; Ahrens I; Bode C; Jackson SP; Peter K
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):e9-15. PubMed ID: 17170374
[TBL] [Abstract][Full Text] [Related]
6. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor.
Xiao Z; Théroux P; Frojmovic M
Thromb Haemost; 1999 Feb; 81(2):281-5. PubMed ID: 10064007
[TBL] [Abstract][Full Text] [Related]
7. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.
Schwarz M; Meade G; Stoll P; Ylanne J; Bassler N; Chen YC; Hagemeyer CE; Ahrens I; Moran N; Kenny D; Fitzgerald D; Bode C; Peter K
Circ Res; 2006 Jul; 99(1):25-33. PubMed ID: 16778135
[TBL] [Abstract][Full Text] [Related]
8. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
[TBL] [Abstract][Full Text] [Related]
9. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
10. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of platelets by the GPIIb/IIIa receptor antagonist Tirofiban reduces leukocyte-endothelial cell interaction in murine antigen-induced arthritis.
Schmitt-Sody M; Metz P; Gottschalk O; Zysk S; Birkenmaier C; Goebl M; von Schulze Pellengahr C; Veihelmann A; Jansson V
Inflamm Res; 2007 Oct; 56(10):414-20. PubMed ID: 18026698
[TBL] [Abstract][Full Text] [Related]
12. [Study on conformational changes of GP IIb/IIIa complex during platelet activation].
Peng L; Li J; Wu H
Zhonghua Xue Ye Xue Za Zhi; 1999 Sep; 20(9):459-61. PubMed ID: 11721407
[TBL] [Abstract][Full Text] [Related]
13. A defined peptide that inhibits the formation of the glycoprotein IIb and IIIa complex.
Chiang TM; Zhu J
Thromb Res; 2005; 115(6):503-8. PubMed ID: 15792682
[TBL] [Abstract][Full Text] [Related]
14. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia.
Mousa SA; Ahmad S
Am J Hematol; 2007 Apr; 82(4):276-82. PubMed ID: 17039513
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3.
Mousa SA; Bozarth JM; Lorelli W; Forsythe MS; Thoolen MJ; Slee AM; Reilly TM; Friedman PA
J Pharmacol Exp Ther; 1998 Sep; 286(3):1277-84. PubMed ID: 9732389
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric assay of platelet glycoprotein receptor numbers in hypercholesterolemia.
Ozsavci D; Yardimci T; Demirel GY; Demiralp E; Uras F; Onder E
Platelets; 2002 Jun; 13(4):223-9. PubMed ID: 12189024
[TBL] [Abstract][Full Text] [Related]
17. Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications.
Haas S; Walenga JM; Jeske WP; Fareed J
Semin Thromb Hemost; 1999; 25 Suppl 1():67-75. PubMed ID: 10357155
[TBL] [Abstract][Full Text] [Related]
18. Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events.
Dunkley S; Evans S; Gaudry L; Jepson N
Platelets; 2005 Dec; 16(8):462-8. PubMed ID: 16287613
[TBL] [Abstract][Full Text] [Related]
19. Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation.
Ito H; Miyakoda G; Mori T
Platelets; 2004 Aug; 15(5):293-301. PubMed ID: 15370100
[TBL] [Abstract][Full Text] [Related]
20. FcgammaRII mediates platelet aggregation caused by disintegrins and GPIIb/IIIa monoclonal antibody, AP2.
Huang TF; Chang CH; Ho PL; Chung CH
Exp Hematol; 2008 Dec; 36(12):1704-13. PubMed ID: 18809237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]